oxidopamine has been researched along with Bradykinesia in 18 studies
Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.
oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Bradykinesia and hypokinesia represent well-known motor symptoms of Parkinson's disease (PD)." | 5.43 | Decreased forelimb ability in mice intracerebroventricularly injected with low dose 6-hydroxidopamine: A model on the dissociation of bradykinesia from hypokinesia. ( Braga, AL; Colle, D; Dias, PF; Farina, M; Ghizoni, H; Godoi, M; Gonçalves, CL; Hort, MA; Naime, AA; Ribeiro, RP; Santos, DB, 2016) |
| " After three weeks as a recovery period, 6-OHDA-induced bradykinesia and balance disturbances were assessed by using beam traversal test 10, 30 and 60 minutes after intraperitoneal injections of the drugs (caffeine, SCH58261)." | 3.83 | Effect of adenosine A2A receptor antagonists on motor disorders induced by 6-hydroxydopamine in rat. ( Mahmoudi, J; Reyhani-Rad, S, 2016) |
| "PNU reversed motor incoordination and hypokinesia induced via the intrastriatal injection of 6-hydroxydopamine and manifested by lower falling latency in the rotarod test, short ambulation time and low rearing incidence in open field test." | 1.72 | The α7 nAChR allosteric modulator PNU-120596 amends neuroinflammatory and motor consequences of parkinsonism in rats: Role of JAK2/NF-κB/GSk3β/ TNF-α pathway. ( Afify, EA; El-Ganainy, SO; El-Sayed, NS; Gowayed, MA; Matar, NA, 2022) |
| "Bradykinesia and hypokinesia represent well-known motor symptoms of Parkinson's disease (PD)." | 1.43 | Decreased forelimb ability in mice intracerebroventricularly injected with low dose 6-hydroxidopamine: A model on the dissociation of bradykinesia from hypokinesia. ( Braga, AL; Colle, D; Dias, PF; Farina, M; Ghizoni, H; Godoi, M; Gonçalves, CL; Hort, MA; Naime, AA; Ribeiro, RP; Santos, DB, 2016) |
| " However, both acute and chronic administration of S33084 enhanced L-DOPA-induced contralateral turning, suggesting potential antiparkinsonian properties." | 1.36 | The selective D(3) receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats. ( Brocco, M; Mela, F; Millan, MJ; Morari, M, 2010) |
| "In a mouse model of Parkinson's disease, direct-pathway activation completely rescued deficits in freezing, bradykinesia and locomotor initiation." | 1.36 | Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry. ( Deisseroth, K; Freeze, BS; Kay, K; Kravitz, AV; Kreitzer, AC; Parker, PR; Thwin, MT, 2010) |
| "These findings support the premise that hypokinesia is associated with an increased STN neuronal activity, and that improvements of parkinsonian motor abnormalities are associated with a decrease in STN activity." | 1.34 | Noradrenergic modulation of subthalamic nucleus activity: behavioral and electrophysiological evidence in intact and 6-hydroxydopamine-lesioned rats. ( Belujon, P; Benazzouz, A; Bezard, E; Bioulac, B; Taupignon, A, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.56) | 18.2507 |
| 2000's | 4 (22.22) | 29.6817 |
| 2010's | 10 (55.56) | 24.3611 |
| 2020's | 3 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Gowayed, MA | 1 |
| El-Sayed, NS | 1 |
| Matar, NA | 1 |
| Afify, EA | 1 |
| El-Ganainy, SO | 1 |
| Di Bisceglie Caballero, S | 1 |
| Ces, A | 1 |
| Liberge, M | 2 |
| Ambroggi, F | 1 |
| Amalric, M | 2 |
| Ouagazzal, AM | 1 |
| Kasanga, EA | 1 |
| Han, Y | 1 |
| Shifflet, MK | 1 |
| Navarrete, W | 1 |
| McManus, R | 1 |
| Parry, C | 1 |
| Barahona, A | 1 |
| Nejtek, VA | 1 |
| Manfredsson, FP | 1 |
| Kordower, JH | 1 |
| Richardson, JR | 1 |
| Salvatore, MF | 1 |
| Schor, JS | 1 |
| Nelson, AB | 1 |
| Grieb, B | 1 |
| Engler, G | 1 |
| Sharott, A | 1 |
| von Nicolai, C | 1 |
| Streichert, T | 1 |
| Papageorgiou, I | 1 |
| Schulte, A | 1 |
| Westphal, M | 1 |
| Lamszus, K | 1 |
| Engel, AK | 1 |
| Moll, CK | 1 |
| Hamel, W | 1 |
| Ribeiro, RP | 1 |
| Santos, DB | 1 |
| Colle, D | 1 |
| Naime, AA | 1 |
| Gonçalves, CL | 1 |
| Ghizoni, H | 1 |
| Hort, MA | 1 |
| Godoi, M | 1 |
| Dias, PF | 1 |
| Braga, AL | 1 |
| Farina, M | 1 |
| Reyhani-Rad, S | 1 |
| Mahmoudi, J | 1 |
| Sanders, TH | 1 |
| Jaeger, D | 1 |
| Ztaou, S | 1 |
| Maurice, N | 1 |
| Camon, J | 1 |
| Guiraudie-Capraz, G | 1 |
| Kerkerian-Le Goff, L | 1 |
| Beurrier, C | 1 |
| Kelsey, JE | 1 |
| Harris, O | 1 |
| Cassin, J | 1 |
| Mela, F | 1 |
| Millan, MJ | 1 |
| Brocco, M | 1 |
| Morari, M | 1 |
| Lin, JW | 1 |
| Shih, CM | 1 |
| Chen, YC | 1 |
| Lin, CM | 1 |
| Tsai, JT | 1 |
| Chiang, YH | 2 |
| Shih, R | 1 |
| Chiu, PL | 1 |
| Hung, KS | 1 |
| Yeh, YS | 1 |
| Wei, L | 1 |
| Chiu, WT | 1 |
| Yang, LY | 1 |
| Kravitz, AV | 1 |
| Freeze, BS | 1 |
| Parker, PR | 1 |
| Kay, K | 1 |
| Thwin, MT | 1 |
| Deisseroth, K | 1 |
| Kreitzer, AC | 1 |
| Sutton, AC | 2 |
| Yu, W | 2 |
| Calos, ME | 2 |
| Smith, AB | 1 |
| Ramirez-Zamora, A | 1 |
| Molho, ES | 2 |
| Pilitsis, JG | 1 |
| Brotchie, JM | 2 |
| Shin, DS | 2 |
| Mueller, LE | 1 |
| Berk, M | 1 |
| Shim, J | 1 |
| Carlen, PL | 1 |
| Wang, Y | 1 |
| Chang, CF | 1 |
| Morales, M | 1 |
| Harvey, BK | 1 |
| Su, TP | 1 |
| Tsao, LI | 1 |
| Chen, S | 1 |
| Thiemermann, C | 1 |
| Belujon, P | 1 |
| Bezard, E | 1 |
| Taupignon, A | 1 |
| Bioulac, B | 1 |
| Benazzouz, A | 1 |
| Caronti, B | 1 |
| Margotta, V | 1 |
| Merante, A | 1 |
| Pontieri, FE | 1 |
| Palladini, G | 1 |
18 other studies available for oxidopamine and Bradykinesia
| Article | Year |
|---|---|
The α7 nAChR allosteric modulator PNU-120596 amends neuroinflammatory and motor consequences of parkinsonism in rats: Role of JAK2/NF-κB/GSk3β/ TNF-α pathway.
Topics: Animals; Dopaminergic Neurons; Glycogen Synthase Kinase 3 beta; Hypokinesia; Isoxazoles; Janus Kinas | 2022 |
Optogenetic Globus Pallidus Stimulation Improves Motor Deficits in 6-Hydroxydopamine-Lesioned Mouse Model of Parkinson's Disease.
Topics: Animals; Corpus Striatum; Dopamine; Globus Pallidus; Hypokinesia; Mice; Optogenetics; Oxidopamine; P | 2023 |
Nigral-specific increase in ser31 phosphorylation compensates for tyrosine hydroxylase protein and nigrostriatal neuron loss: Implications for delaying parkinsonian signs.
Topics: Animals; Dopamine; Hypokinesia; Neurons; Oxidopamine; Phosphorylation; Rats; Substantia Nigra; Tyros | 2023 |
Multiple stimulation parameters influence efficacy of deep brain stimulation in parkinsonian mice.
Topics: Animals; Behavior, Animal; Deep Brain Stimulation; Disease Models, Animal; Electrodes; Humans; Hypok | 2019 |
High-frequency stimulation of the subthalamic nucleus counteracts cortical expression of major histocompatibility complex genes in a rat model of Parkinson's disease.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Electric Stimulation Therapy; Electrodes; Electro | 2014 |
Decreased forelimb ability in mice intracerebroventricularly injected with low dose 6-hydroxidopamine: A model on the dissociation of bradykinesia from hypokinesia.
Topics: Adrenergic Agents; Animals; Dose-Response Relationship, Drug; Exploratory Behavior; Feeding Behavior | 2016 |
Effect of adenosine A2A receptor antagonists on motor disorders induced by 6-hydroxydopamine in rat.
Topics: Adenosine A2 Receptor Antagonists; Animals; Caffeine; Disease Models, Animal; Hypokinesia; Male; Mot | 2016 |
Optogenetic stimulation of cortico-subthalamic projections is sufficient to ameliorate bradykinesia in 6-ohda lesioned mice.
Topics: Animals; Deep Brain Stimulation; Disease Models, Animal; Humans; Hypokinesia; Male; Mice, Inbred C57 | 2016 |
Involvement of Striatal Cholinergic Interneurons and M1 and M4 Muscarinic Receptors in Motor Symptoms of Parkinson's Disease.
Topics: Adrenergic Agents; Amphetamine; Analysis of Variance; Animals; Choline O-Acetyltransferase; Choliner | 2016 |
The CB(1) antagonist rimonabant is adjunctively therapeutic as well as monotherapeutic in an animal model of Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Hypokinesia; Levodopa; Male; Motor Activity; Oxido | 2009 |
The selective D(3) receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats.
Topics: Animals; Antiparkinson Agents; Benzopyrans; Disability Evaluation; Dopamine Antagonists; Dose-Respon | 2010 |
Biochemical alteration in cerebrospinal fluid precedes behavioral deficits in Parkinsonian rats induced by 6-hydroxydopamine.
Topics: Animals; Biomarkers; Cell Count; Cell Death; Disease Models, Animal; Dopamine; Homovanillic Acid; Hy | 2009 |
Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry.
Topics: Animals; Basal Ganglia; Channelrhodopsins; Chromosomes, Artificial, Bacterial; Disease Models, Anima | 2010 |
Deep brain stimulation of the substantia nigra pars reticulata improves forelimb akinesia in the hemiparkinsonian rat.
Topics: Animals; Antipsychotic Agents; Beta Rhythm; Deep Brain Stimulation; Forelimb; Hypokinesia; Male; Oxi | 2013 |
Elevated potassium provides an ionic mechanism for deep brain stimulation in the hemiparkinsonian rat.
Topics: Animals; Beta Rhythm; Deep Brain Stimulation; Forelimb; Hypokinesia; Male; Motor Activity; Oxidopami | 2013 |
Diadenosine tetraphosphate protects against injuries induced by ischemia and 6-hydroxydopamine in rat brain.
Topics: Animals; Apoptosis; Blood Pressure; Brain Ischemia; Cell Hypoxia; Cells, Cultured; Cerebral Cortex; | 2003 |
Noradrenergic modulation of subthalamic nucleus activity: behavioral and electrophysiological evidence in intact and 6-hydroxydopamine-lesioned rats.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Behavior, Animal; Electrophysiolog | 2007 |
Treatment with 6-hydroxydopamine in planaria (Dugesia gonocephala s.l.): morphological and behavioral study.
Topics: Animals; Behavior, Animal; Catecholamines; Dopamine Uptake Inhibitors; Hypokinesia; Motor Activity; | 1999 |